Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Acquisitions & Divestments (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Change in Acquisitions & Divestments for 8 consecutive years, with $70.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 39.66% to $70.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $400.0 million, a 6.54% decrease, with the full-year FY2025 number at $400.0 million, down 6.54% from a year prior.
  • Change in Acquisitions & Divestments was $70.0 million for Q4 2025 at Iovance Biotherapeutics, down from $120.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $164.4 million in Q1 2023 to a low of $21.0 million in Q3 2023.
  • A 3-year average of $92.8 million and a median of $100.0 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Biggest YoY gain for Change in Acquisitions & Divestments was 425.06% in 2024; the steepest drop was 47.07% in 2024.
  • Iovance Biotherapeutics' Change in Acquisitions & Divestments stood at $38.0 million in 2023, then surged by 205.26% to $116.0 million in 2024, then crashed by 39.66% to $70.0 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Change in Acquisitions & Divestments are $70.0 million (Q4 2025), $120.0 million (Q3 2025), and $90.0 million (Q2 2025).